

## Who can administer

May be administered by registered competent doctor or nurse/midwife

## Important information

- **There are two intravenous ibandronic acid preparations** available - **Bonviva and Bondronat**
- Bonviva is licensed for the treatment of osteoporosis
- Bondronat is licensed for the treatment of Tumour Induced Hypercalcaemia, and for the prevention of skeletal related events in patients with breast cancer or bone metastases
- **Only Bonviva** is available in GUH, and this preparation should only be used for **osteoporosis**
- See under 'Dose' for adjustments required in **renal** impairment
- Ensure pre-counselling and baseline assessment for risk of adverse reactions such as **osteonecrosis of the jaw and external auditory canal**

## Available preparations

Bonviva 3mg per 3mL pre-filled syringe

Bondronat 2mg per 2mL vial - not stocked in GUH

Bondronat 6mg per 6mL vial - not stocked in GUH

## Reconstitution

Already in solution

## Infusion fluids

Not required - product ready for use (Bonviva)

## Methods of intravenous administration

### **Bolus intravenous injection (Bonviva only)**

- Administer over 15 to 30 seconds

## Dose in adults

### **Treatment of osteoporosis in postmenopausal women at increased risk of fracture**

- Give 3mg by bolus intravenous injection every three months

### **Renal impairment**

- Not recommended for patients with Creatinine clearance less than 30mL/minute

## Further information

- All patients must receive continuous supplemental calcium and Vitamin D



- Influenza like symptoms have been reported, typically in association with the first dose
- Existing hypocalcaemia must be corrected before starting Bonviva

## Storage

Store below 25<sup>0</sup>C

## References

SPC 29/03/2021

## Therapeutic classification

Bisphosphonate